FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022795714> ?p ?o ?g. }

• W3022795714 endingPage "938" @default.
• W3022795714 startingPage "928" @default.
• W3022795714 abstract "Tuberculosis (TB) is a life-threatening disease resulting in an estimated 10 million new infections and 1.8 million deaths annually, primarily in underdeveloped countries. The economic burden of TB has been estimated as approximately 12 billion USD annually in direct and indirect costs. Additionally, multi-drug-resistant (MDR) and extreme-drug-resistant (XTR) TB strains resulting in about 250 000 deaths annually are now widespread, increasing pressure on the identification of new anti-TB agents that operate by a novel mechanism of action. Chrysomycin A is a rare C-aryl glycoside first discovered over 60 years ago. In a recent high-throughput screen, we found that chrysomycin A has potent anti-TB activity, with minimum inhibitory concentration (MIC) = 0.4 μg/mL against MDR-TB strains. However, chrysomycin A is obtained in low yields from fermentation of Streptomyces, and the mechanism of action of this compound is unknown. To facilitate the mechanism of action and preclinical studies of chrysomycin A, we developed a 10-step, scalable synthesis of the isolate and its two natural congeners polycarcin V and gilvocarcin V. The synthetic sequence was enabled by the implementation of two sequential C–H functionalization steps as well as a late-stage C-glycosylation. In addition, >10 g of the advanced synthetic intermediate has been prepared, which greatly facilitated the synthesis of 33 new analogues to date. The structure–activity relationship was subsequently delineated, leading to the identification of derivatives with superior potency against MDR-TB (MIC = 0.08 μg/mL). The more potent derivatives contained a modified carbohydrate residue which suggests that further optimization is additionally possible. The chemistry we report here establishes a platform for the development of a novel class of anti-TB agents active against drug-resistant pathogens." @default.
• W3022795714 created "2020-05-13" @default.
• W3022795714 creator A5005968118 @default.
• W3022795714 creator A5015914574 @default.
• W3022795714 creator A5020188195 @default.
• W3022795714 creator A5023579325 @default.
• W3022795714 creator A5034764240 @default.
• W3022795714 creator A5040572160 @default.
• W3022795714 creator A5049759564 @default.
• W3022795714 creator A5050399832 @default.
• W3022795714 creator A5054873038 @default.
• W3022795714 creator A5067939471 @default.
• W3022795714 creator A5070025475 @default.
• W3022795714 creator A5080798079 @default.
• W3022795714 creator A5080816898 @default.
• W3022795714 date "2020-05-04" @default.
• W3022795714 modified "2023-10-12" @default.
• W3022795714 title "Chrysomycin A Derivatives for the Treatment of Multi-Drug-Resistant Tuberculosis" @default.
• W3022795714 cites W1236120779 @default.
• W3022795714 cites W175749650 @default.
• W3022795714 cites W1976047686 @default.
• W3022795714 cites W1982175059 @default.
• W3022795714 cites W1996794817 @default.
• W3022795714 cites W2001818849 @default.
• W3022795714 cites W2025804869 @default.
• W3022795714 cites W2027263177 @default.
• W3022795714 cites W2029488165 @default.
• W3022795714 cites W2034280981 @default.
• W3022795714 cites W2050102671 @default.
• W3022795714 cites W2053878100 @default.
• W3022795714 cites W2054207726 @default.
• W3022795714 cites W2064155054 @default.
• W3022795714 cites W2066781511 @default.
• W3022795714 cites W2071202191 @default.
• W3022795714 cites W2071394091 @default.
• W3022795714 cites W2073009911 @default.
• W3022795714 cites W2079965576 @default.
• W3022795714 cites W2083705102 @default.
• W3022795714 cites W2089392594 @default.
• W3022795714 cites W2094175798 @default.
• W3022795714 cites W2101564706 @default.
• W3022795714 cites W2109255397 @default.
• W3022795714 cites W2114134108 @default.
• W3022795714 cites W2132269237 @default.
• W3022795714 cites W2136522707 @default.
• W3022795714 cites W2154344931 @default.
• W3022795714 cites W2164397815 @default.
• W3022795714 cites W2170261800 @default.
• W3022795714 cites W2306317410 @default.
• W3022795714 cites W2313971938 @default.
• W3022795714 cites W2323646210 @default.
• W3022795714 cites W2328714476 @default.
• W3022795714 cites W2329276036 @default.
• W3022795714 cites W2402273647 @default.
• W3022795714 cites W2415126412 @default.
• W3022795714 cites W2470533104 @default.
• W3022795714 cites W2527005516 @default.
• W3022795714 cites W2624370041 @default.
• W3022795714 cites W2736985370 @default.
• W3022795714 cites W2768426391 @default.
• W3022795714 cites W2777355472 @default.
• W3022795714 cites W2900482408 @default.
• W3022795714 cites W2951701001 @default.
• W3022795714 cites W2951717815 @default.
• W3022795714 cites W2953276288 @default.
• W3022795714 cites W3017783322 @default.
• W3022795714 cites W4205602318 @default.
• W3022795714 cites W4362082402 @default.
• W3022795714 doi "https://doi.org/10.1021/acscentsci.0c00122" @default.
• W3022795714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7318084" @default.
• W3022795714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32607440" @default.
• W3022795714 hasPublicationYear "2020" @default.
• W3022795714 type Work @default.
• W3022795714 sameAs 3022795714 @default.
• W3022795714 citedByCount "38" @default.
• W3022795714 countsByYear W30227957142020 @default.
• W3022795714 countsByYear W30227957142021 @default.
• W3022795714 countsByYear W30227957142022 @default.
• W3022795714 countsByYear W30227957142023 @default.
• W3022795714 crossrefType "journal-article" @default.
• W3022795714 hasAuthorship W3022795714A5005968118 @default.
• W3022795714 hasAuthorship W3022795714A5015914574 @default.
• W3022795714 hasAuthorship W3022795714A5020188195 @default.
• W3022795714 hasAuthorship W3022795714A5023579325 @default.
• W3022795714 hasAuthorship W3022795714A5034764240 @default.
• W3022795714 hasAuthorship W3022795714A5040572160 @default.
• W3022795714 hasAuthorship W3022795714A5049759564 @default.
• W3022795714 hasAuthorship W3022795714A5050399832 @default.
• W3022795714 hasAuthorship W3022795714A5054873038 @default.
• W3022795714 hasAuthorship W3022795714A5067939471 @default.
• W3022795714 hasAuthorship W3022795714A5070025475 @default.
• W3022795714 hasAuthorship W3022795714A5080798079 @default.
• W3022795714 hasAuthorship W3022795714A5080816898 @default.
• W3022795714 hasBestOaLocation W30227957141 @default.
• W3022795714 hasConcept C114851261 @default.
• W3022795714 hasConcept C142724271 @default.
• W3022795714 hasConcept C185592680 @default.
• W3022795714 hasConcept C194671627 @default.

• next